COMP <GO>
GMED vs BAX // ALTMAN Z-SCORE & DEBT/EQUITY
Globus Medical Inc. (NYSE) VS. Baxter International Inc. (NYSE) • 15-METRIC TALLY: GMED 11
— BAX 2
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: GMED
LAST: $78.05 (-5.86%) • MKT CAP: $10.48B
balance-sheet
10.74
LAST: $23.00 (-2.13%) • MKT CAP: $11.90B
balance-sheet
2.22
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GMED VS. BAX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GMED | BAX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 67.40% | 30.10% | +37.30 | GMED | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.70% | -2.40% | +11.10 | GMED | /roic <GO> |
| EV/EBITDA & P/E Valuation | 17.6x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 5.29% | 2.79% | +2.50 | GMED | /fcf-yield <GO> |
| Operating Margin | 16.30% | -2.70% | +19.00 | GMED | /operating-margins <GO> |
| Net Profit Margin | 18.30% | -8.50% | +26.80 | GMED | /net-margins <GO> |
| Revenue Growth (YoY) | 16.70% | 5.70% | +11.00 | GMED | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.86% | -2.86 | BAX | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 10.74 | 2.22 | +8.52 | GMED | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 6/9 | +3.00 | GMED | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.0 | 39.0 | +9.00 | GMED | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 0.95 | +0.12 | GMED | /macro-sensitivity <GO> |
| Forward P/E Multiple | 17.4x | 18.0x | -0.60 | GMED | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.48B | $11.90B | -$1.42B | BAX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GMED REV | BAX REV | GMED GROSS % | BAX GROSS % | GMED FCF | BAX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.94B | $11.24B | 67.4% | 30.1% | $588.8M | $339.0M |
| FY 2024 | $2.52B | $10.64B | 58.9% | 37.5% | $405.2M | $540.4M |
| FY 2023 | $1.57B | $10.36B | — | — | $172.9M | $1.26B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GMED // BETA 1.07
BAX // BETA 0.95